接受托法替布治疗的银屑病关节炎患者不同疾病活动度轨迹的识别:两项3期研究的事后分析
该事后分析汇总两项3期研究(OPAL Broaden、OPAL Beyond)中接受托法替布5 mg或10 mg每日两次的银屑病关节炎患者数据(n=225、n=226),采用基于组的轨迹模型分析至第6个月的银屑病关节炎疾病活动度评分(PASDAS),识别出5个轨迹组。5 mg和10 mg每日两次模型显示可比的轨迹和基线特征;高疾病活动度患者中,附着点炎和压痛关节计数可能影响托法替布应答的时机和/或幅度。
要点
- 两种托法替布剂量均识别出5个轨迹组,从中度活动度改善至极低/低疾病活动度,至高疾病活动度持续。
- 第4/5组基线PsA临床领域评分普遍显著高于第1–3组,但银屑病面积和严重度指数/甲银屑病严重度指数除外。
- 高疾病活动度患者中,附着点炎和压痛关节计数可能影响托法替布应答的时机和/或幅度。
核心结论
- 接受托法替布治疗的银屑病关节炎患者中识别出5个不同的轨迹组,具有不同的基线特征和治疗结局,但不良事件无明确趋势。
- 托法替布5 mg和10 mg每日两次模型显示可比的轨迹和基线特征。
- 高疾病活动度患者中,附着点炎和压痛关节计数可能影响托法替布应答的时机和/或幅度。
研究设计与样本
- 两项3期研究(OPAL Broaden、OPAL Beyond)的事后汇总分析。
- 患者接受托法替布5 mg或10 mg每日两次(n=225、n=226)。
- 采用基于组的轨迹模型分析至第6个月的银屑病关节炎疾病活动度评分(PASDAS),基于疾病状态(极低/低/中度/高疾病活动度,即VLDA/LDA/MoDA/HDA)识别不同治疗应答组。
- 评估基线特征、至第6个月的PASDAS组分和不良事件(AEs)。
主要发现
- 两种托法替布剂量均识别出5个轨迹组:第1组从MoDA改善至VLDA/LDA;第2组从HDA改善至VLDA;第3组从HDA快速改善至MoDA;第4组从HDA逐渐改善至MoDA;第5组持续HDA。
- 第4/5组基线PsA临床领域评分普遍显著高于第1–3组,但银屑病面积和严重度指数/甲银屑病严重度指数除外。
- 第4组基线利兹附着点炎指数/加拿大脊柱关节炎研究联盟附着点炎评分和压痛关节计数显著高于第2组。
- 所有组PASDAS组分至第6个月普遍改善,与建模轨迹一致。
- 各组间不良事件无明确趋势。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To capture variations in tofacitinib treatment response in psoriatic arthritis (PsA) by identifying patient groups with distinct disease activity trajectories. METHODS: Data were pooled post hoc from two phase 3 studies (OPAL Broaden, OPAL Beyond) in patients with PsA receiving tofacitinib 5 or 10 mg twice daily (n=225, n=226, respectively). Psoriatic Arthritis Disease Activity Score (PASDAS) to month 6 was used in group-based trajectory modelling to identify distinct treatment response groups based on disease state (very low/low/moderate/high disease activity (VLDA/LDA/MoDA/HDA, respectively)). Baseline characteristics, PASDAS components to month 6 and adverse events (AEs) were assessed. RESULTS: Five trajectory groups were identified for both tofacitinib doses: groups improved from MoDA→VLDA/LDA (group 1); HDA→VLDA (group 2); HDA→MoDA rapidly (group 3) or gradually (group 4) or remained in HDA (group 5). Groups 4/5 generally had significantly higher baseline PsA clinical domain scores than groups 1‒3, except for Psoriasis Area and Severity Index/Nail Psoriasis Severity Index. Baseline Leeds Enthesitis Index/Spondyloarthritis Research Consortium of Canada enthesitis scores and tender joint counts were significantly higher in group 4 vs group 2. PASDAS components generally improved to month 6 in all groups, consistent with modelled trajectories. There were no clear trends in AEs across groups. CONCLUSIONS: In patients with PsA receiving tofacitinib, five distinct trajectory groups were identified with different baseline characteristics and treatment outcomes, but no clear trends in AEs. The tofacitinib 5 and 10 mg twice daily models showed comparable trajectories and baseline characteristics. In patients with HDA, enthesitis and tender joint count may impact timing and/or magnitude of response to tofacitinib. Identifying characteristics that impact treatment response may aid personalised treatment algorithm development. TRIAL REGISTRATION NUMBERS: NCT01877668/NCT01882439.
引用
- Gladman D, Tillett W, Gruben D, et al. Identification of distinct disease activity trajectories in patients with psoriatic arthritis receiving tofacitinib: a post hoc analysis of two phase 3 studies. RMD Open. 2025. PMID: 40461265. doi:10.1136/rmdopen-2024-005250
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。